Publication: Controlled release of interleukin-2 from chitosan microspheres
| dc.contributor.author | ÖZBAŞ, SUNA | |
| dc.contributor.authors | Ozbas-Turan, S; Akbuga, J; Aral, C | |
| dc.date.accessioned | 2022-03-12T16:59:00Z | |
| dc.date.accessioned | 2026-01-11T19:10:30Z | |
| dc.date.available | 2022-03-12T16:59:00Z | |
| dc.date.issued | 2002 | |
| dc.description.abstract | Chitosan microspheres were evaluated for sustained-release of recombinant human interleukin-2 (rIL-2) in this study. In addition, the effects of different formulation factors, such as chitosan and protein concentrations, the volume of sodium sulfate solution, addition technique of rIL-2, and presence of glutaraldehyde during the encapsulation process, on microsphere characteristics were investigated. Chitosan microspheres containing rIL-2 were prepared by using the precipitation technique. The average diameter of microspheres was between 1.11-1.59 mum. Recombinant IL-2 encapsulation efficiency in these micropheres was high (75-98%). Formulation factors had no effect on the microsphere size. Recombinant IL-2 had been released from chitosan microspheres over a period of 3 months. The encapsulated rIL-2 remained biologically active and could be completely recovered from the release medium. Briefly, rIL-2 was released from chitosan microspheres in a sustained manner. The efficacy of rIL-2 loaded chitosan microspheres was studied using two model cells, HeLa and L-strain cell lines. Chitosan microspheres were added to the cells at different concentrations, and the amount of rIL-2 was assayed using the ELISA kit. Cell culture studies indicated that microspheres were uptaken by cells, and rIL-2 was released from the microspheres. Cellular uptake of rIL-2-loaded microspheres was dose dependent. It can be said that chitosan microsphere is a suitable carrier for rIL-2 delivery. (C) 2002 Wiley-Liss, Inc. and the American Pharmaceutical Association. | |
| dc.identifier.doi | 10.1002/jps.10122 | |
| dc.identifier.issn | 0022-3549 | |
| dc.identifier.pubmed | 11977100 | |
| dc.identifier.uri | https://hdl.handle.net/11424/227136 | |
| dc.identifier.wos | WOS:000175407400005 | |
| dc.language.iso | eng | |
| dc.publisher | JOHN WILEY & SONS INC | |
| dc.relation.ispartof | JOURNAL OF PHARMACEUTICAL SCIENCES | |
| dc.rights | info:eu-repo/semantics/closedAccess | |
| dc.subject | interleukin-2 | |
| dc.subject | chitosan microspheres | |
| dc.subject | precipitation technique | |
| dc.subject | PREDNISOLONE SODIUM-PHOSPHATE | |
| dc.subject | BIODEGRADABLE MICROSPHERES | |
| dc.subject | RECOMBINANT INTERLEUKIN-2 | |
| dc.subject | IMMUNOTHERAPY | |
| dc.subject | ENHANCEMENT | |
| dc.subject | LIPOSOMES | |
| dc.subject | DELIVERY | |
| dc.subject | INVIVO | |
| dc.subject | CANCER | |
| dc.subject | MODEL | |
| dc.title | Controlled release of interleukin-2 from chitosan microspheres | |
| dc.type | article | |
| dspace.entity.type | Publication | |
| oaire.citation.endPage | 1251 | |
| oaire.citation.issue | 5 | |
| oaire.citation.startPage | 1245 | |
| oaire.citation.title | JOURNAL OF PHARMACEUTICAL SCIENCES | |
| oaire.citation.volume | 91 |
